Refine
Year of publication
- 2021 (2) (remove)
Document Type
- Doctoral Thesis (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Staphylococcus aureus (2) (remove)
Our modern understanding of the hygiene hypothesis is that bacteria are not only the cause of disease but also essential for a healthy immune response and regulation. Varied microbial exposure prenatally and in early childhood protects us from pathological immune reactions such as autoimmune diseases and allergies. Against this background, the hypothesis that bacteria can act as allergens appears paradoxical. Nevertheless, there is growing evidence that Staphylococcus aureus (S. aureus) is associated with allergic reactions and serine protease-like proteins (Spls) produced by S. aureus have been identified as pacemakers of allergic reactions. To open prospects for treatment or causal therapy in patients at risk, the underlying mechanism of allergy induction by Spls was studied, focusing on the IL-33 pathway in airway inflammation. In a murine asthma model C57BL/6 J wild-type mice were repeatedly exposed to SplD via intratracheal application. After two weeks a Th2-biased inflammatory response was observed in the airways: IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell hyperplasia. Blocking IL-33 activity with its soluble receptor ST2 counteracted these effects: significantly decreased numbers of eosinophils, IL-13+ type 2 ILCs, IL-13+CD4+ T cells as well as reduced IL-5 and IL-13 production by lymph node cells were observed. This study indicates that SplD induces allergic airway inflammation via the IL-33/ST2 axis. IL-33 upregulation was not accompanied by cell death, which indicates that IL-33 may not be passively released by dying cells but actively secreted by the airway epithelium. Future identification of the physiological substrates of the Spls may help to shed light on the source of IL-33 in SplD-induced airway inflammation.
While the causes of allergy induction by S. aureus Spls were addressed by investigating the underlying mechanism, the consequences of this were also of interest: Does the pro-allergenic response to S. aureus affect patients exposed to S. aureus in their airways? Therefore, the humoral and cellular immune response against Spls was studied in cystic fibrosis (CF) patients who are more frequently colonized with S. aureus than the healthy population and suffer from frequent recurrent airway infections. In this patient cohort a Th2 shift of the Spl-specific immune response became evident, including high Spl-specific serum IgE levels, strong induction of Th2 cell differentiation and production of type 2 cytokines following ex vivo stimulation with recombinant Spls. The observed response seems to be specific for Spls rather than being a general feature of S. aureus proteases since other putative allergens of S. aureus (ScpA, SspB) did not show increased IgE binding in CF sera. The Th2-driven immune response might impede antibacterial clearance and worsen the clinical picture. Larger clinical studies are needed to validate this notion by correlating the anti-S. aureus immune response with clinical parameters and testing new therapy options.
These results and findings shed light on a novel, possibly underestimated facet of the immune response against S. aureus and give impetus for further research on bacterial allergens in general, reaching beyond the species S. aureus.
Staphylococcus aureus (S. aureus) is among the most common infectious agents, burdening the
global health care system and challenging physicians. Thus, the demand for vaccination is
increasing, and despite many attempts, no vaccine is currently available. The iron-regulated
surface determinant protein B (IsdB) is a highly conserved surface protein of S. aureus. It has
an essential role in bacterial iron acquisition and cell attachment, functioning as a fitness factor.
It has been shown that IsdB is critical for S. aureus virulence and growth in iron-restricted
conditions, such as the human host. Therefore, IsdB was studied as a vaccine candidate. A nonadjuvant vaccine (V710) was developed based on IsdB, which showed promising results in the
preclinical, phase I, and phase IIa trials. Unexpectedly, in a phase IIb/III, in cardiothoracic
surgery patients that were infected by S. aureus, mortality was significantly higher in the
vaccinated group than the placebo. Despite increased antibody levels against IsdB in the
vaccinated patients, V710 failed to prevent S. aureus infection. Therefore, a better
understanding of the interaction between S. aureus and the immune system is required.
We have discovered that IsdB has an important role in host-pathogen interaction. This bacterial
protein activated human monocytes and murine bone marrow-derived dendritic cells
(mBMDCs) to produce proinflammatory cytokines, such as IL-6, TNF-α, IL-12, IL-23, IL-33,
and IL-1β. In silico molecular docking and DimPlot analysis predicted that IsdB binds to -TLR4
via non-covalent interactions. Microscale thermophoresis confirmed that IsdB has a high
affinity to recombinant human TLR4 in the nanomolar range. Inhibition of TLR4 completely
abolished the production of all the cytokines mentioned above in both cell types. Furthermore,
we characterized the TLR4 signaling pathway triggered by IsdB. In human monocytes, blocking
the myeloid differentiation factor 88 (MyD88) adaptor protein and NF-κβ transcription factor
caused complete abrogation of proinflammatory cytokines in response to IsdB, revealing that
IsdB induces cytokine release via the TLR4-MyD88-NF-κβ dependent pathway.
The consistent release of IL-1β suggested that IsdB induced activation of the inflammasome, a
multi-molecular complex known to play a crucial role in innate immunity. We corroborated our
observations in human monocytes and mBMDCs by inhibiting essential components of the
NLRP3 inflammasome. Blocking NLRP3, caspases in general and caspase-1 completely
inhibited the release of IL-1β. In monocytes, IsdB alone was sufficient to induce NLRPdependent IL-1β release, suggesting an alternative pathway of inflammasome activation. In
contrast, mBMDCs required an additional stimulus, such as ATP or MSU (known stress
signals) besides IsdB, to release IL-1β, indicating a classical inflammasome activation. These
results demonstrate that IsdB induces the release of IL-1β via the TLR4-NLRP3-Caspase-1
axis. Next, we addressed the molecular mechanisms involved in IsdB-induced IL-1β in monocytes.
A low concentration of intracellular potassium (K+) resulting from K+ efflux is known to trigger the NLRP3 inflammasome-mediated IL-1β release. We demonstrated that blocking potassium efflux by inhibition of ion channels, such as pannexin channels (P2X)7, and addition of extracellular KCl significantly reduced IsdB-induced IL-1β. Other common inflammasome activators, such as phagolysosome rupture and reactive oxygen species (ROS), did not contribute to the release of IL-1β in response to IsdB. In summary, we revealed yet another role of IsdB beyond iron acquisition from Hb and attachment to the host cells via vitronectin and integrins. It is conceivable that IsdB’s interaction with innate immune cells modulates the quality of the adaptive immune response, showing a new facet in the pathogen-host relationship of S. aureus that should be considered in future
vaccine development.